Issue of Shares

Summary by AI BETAClose X

Wellnex Life Limited has agreed to a full and final settlement with former corporate advisors by issuing 3,071,336 ordinary shares at A$0.074 per share, the closing price on March 26, 2026. These new shares, which will rank pari passu with existing shares, are being issued under the company's existing placement capacity and will be admitted to trading on AIM around April 2, 2026. Following this issuance, Wellnex Life's total issued share capital will be 73,026,812 ordinary shares.

Disclaimer*

Wellnex Life Limited
27 March 2026
 

                                                                       

ASX/AIM Announcement                                                                                  27 March 2026

 

Issue of Shares

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") announces that it is has agreed full and final settlement with former corporate advisors regarding outstanding fees relating to past corporate advisory and capital-raising services.

Wellnex Life will issue a total of 3,071,336 fully paid ordinary shares (New Shares) at a reference price (deemed issue price) of A$0.074 per New Share being the ASX closing price on 26 March 2026. The New Shares will be issued under the Company's existing Listing Rule 7.1 placement capacity.

AIM Application and Total Voting Rights

Application has been made for the admission of the New Shares to trading on AIM. It is expected that, admission will become effective and dealings in the New Shares will commence on AIM at 8.00 a.m. (UK time) on or around 2 April 2026. An Appendix 3B will be lodged with the ASX separately in relation to the issue of Shares.

The New Shares are being issued fully paid and ranking pari passu in all respects with the Company's existing ordinary shares.

Following Admission, the Company's issued share capital will comprise of 73,026,812 ordinary shares, none of which are held in treasury. Accordingly, the figure of 73,026,812 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules and the provisions of the Company's constitution.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)                            

Eric Jiang                                                                             

Interim Executive Chairman                                                            

E: eric.j@wellnexlife.com.au    

 

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson                                      Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint Broker)                                 swykeham@oranacorp.com

Sebastian Wykeham    

 

S.P. Angel Corporate Finance LLP (Joint Broker)         Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings